Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Binding affinity in drug design: experimental and computational techniques.

Kairys V, Baranauskiene L, Kazlauskiene M, Matulis D, Kazlauskas E.

Expert Opin Drug Discov. 2019 Aug;14(8):755-768. doi: 10.1080/17460441.2019.1623202. Epub 2019 May 31.

PMID:
31146609
2.

Genetic Dissection of the Type III-A CRISPR-Cas System Csm Complex Reveals Roles of Individual Subunits.

Mogila I, Kazlauskiene M, Valinskyte S, Tamulaitiene G, Tamulaitis G, Siksnys V.

Cell Rep. 2019 Mar 5;26(10):2753-2765.e4. doi: 10.1016/j.celrep.2019.02.029.

3.

A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems.

Kazlauskiene M, Kostiuk G, Venclovas Č, Tamulaitis G, Siksnys V.

Science. 2017 Aug 11;357(6351):605-609. doi: 10.1126/science.aao0100. Epub 2017 Jun 29.

PMID:
28663439
4.

Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition.

Kazlauskiene M, Tamulaitis G, Kostiuk G, Venclovas Č, Siksnys V.

Mol Cell. 2016 Apr 21;62(2):295-306. doi: 10.1016/j.molcel.2016.03.024.

5.

Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus.

Tamulaitis G, Kazlauskiene M, Manakova E, Venclovas Č, Nwokeoji AO, Dickman MJ, Horvath P, Siksnys V.

Mol Cell. 2014 Nov 20;56(4):506-17. doi: 10.1016/j.molcel.2014.09.027. Epub 2014 Nov 6.

Supplemental Content

Loading ...
Support Center